Michael W. Lu
Impact in
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 8
- HER2/EGFR in Cancer Research 8
- Cancer Treatment and Pharmacology 2
-
- Lung Cancer Treatments and Mutations 4
- Radiation Therapy and Dosimetry 1
- Co-authors
- Ian E. Krop (5 shared papers)Ellie Guardino (4 shared papers)Véronique Dièras (3 shared papers)David Miles (3 shared papers)Do‐Youn Oh (3 shared papers)Mark D. Pegram (3 shared papers)Steven R. Olsen (3 shared papers)Luca Gianni (3 shared papers)
- Journals
- Journal of Clinical Oncology (6 papers)Clinical Cancer Research (2 papers)PM&R (1 paper)Clinical Pharmacology & Therapeutics (1 paper)Nature (1 paper)
- Partner nations
- United StatesSwitzerlandFrance
In The Last Decade
Michael W. Lu
18 papers receiving 3.8k citations
Michael W. Lu's Hit Papers
Peers
Comparison fields: 5 of 103
- Oncology 2.6k
- Radiology, Nuclear Medicine and Imaging 1.3k
- Health Informatics 48
- Cancer Research 425
- Pulmonary and Respiratory Medicine 846
Countries citing papers authored by Michael W. Lu
This map shows the geographic impact of Michael W. Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Lu more than expected).
Fields of papers citing papers by Michael W. Lu
This network shows the impact of papers produced by Michael W. Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Lu. The network helps show where Michael W. Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael W. Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 2843 |
| 2 | 2012 | 287 | |
| 3 | Evaluating eligibility criteria of oncology trials using real-world data and AI Hit paper breakdown → | 2021 | 208 |
| 4 | 2018 | 185 | |
| 5 | 2012 | 80 | |
| 6 | 2019 | 74 | |
| 7 | 2012 | 67 | |
| 8 | 2012 | 58 | |
| 9 | 2012 | 29 | |
| 10 | 2017 | 26 | |
| 11 | 2008 | 20 | |
| 12 | 2010 | 15 | |
| 13 | 2022 | 14 | |
| 14 | 2016 | 14 | |
| 15 | 2020 | 2 | |
| 16 | 2019 | 1 | |
| 17 | 2023 | 1 | |
| 18 | 2018 | 1 | |
| 19 | 2025 | 0 |
About Michael W. Lu
Michael W. Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Statistics and Probability and Radiology, Nuclear Medicine and Imaging, having authored 19 papers that have together received 3.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (8 papers), Cancer Genomics and Diagnostics (4 papers), Lung Cancer Treatments and Mutations (4 papers), Statistical Methods in Clinical Trials (2 papers), Cancer Treatment and Pharmacology (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (1 paper), Radiomics and Machine Learning in Medical Imaging (1 paper) and Radiation Therapy and Dosimetry (1 paper). The work is most often cited by research in Oncology (2.6k citations), Radiology, Nuclear Medicine and Imaging (1.3k citations), Health Informatics (48 citations), Cancer Research (425 citations) and Pulmonary and Respiratory Medicine (846 citations). Michael W. Lu has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Ian E. Krop, Ellie Guardino, Véronique Dièras, David Miles, Do‐Youn Oh, Mark D. Pegram, Steven R. Olsen, Luca Gianni, Sunil Verma and Fang Ting Liang. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, PM&R, Clinical Pharmacology & Therapeutics and Nature.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.